People · Operator
Named in public records as an officer, director or promoter · active 2018–2019 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Pliant Therapeutics, Inc. | — | Biotechnology | Series D+ | $162.6M | $4.1B | 2018 |
Johannes Hull at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Johannes Hull on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Hoyoung Huh | 1 | 7 |
| NEIL EXTER | 1 | 5 |
| Kevin Raidy | 1 | 4 |
| Charles Homcy | 1 | 4 |
| Gayle Crowell | 1 | 3 |
| Suzanne Bruhn | 1 | 2 |
| John Curnutte | 1 | 2 |
| Bernard Coulie | 1 | 2 |
| Barbara Howes | 1 | 1 |
| Keith Cummings | 1 | 1 |
| Smital Shah | 1 | 1 |
| Eric Lefebvre | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.